NCT03333200 Longitudinal Study of Neurodegenerative Disorders
| NCT ID | NCT03333200 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | MLD |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2012-01-11 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2012-01-11 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.
Eligibility Criteria
Inclusion Criteria: * Any patient with a genetic neurodegenerative disorder Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03333200 clinical trial?
This trial is open to participants of all sexes, studying MLD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03333200 currently recruiting?
Yes, NCT03333200 is actively recruiting participants. Contact the research team at rajands@upmc.edu for enrollment information.
Where is the NCT03333200 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT03333200 clinical trial?
NCT03333200 is sponsored by University of Pittsburgh. The trial plans to enroll 1,500 participants.